Gujarat Themis Biosyn Limited — Others, 19-08-2025: Shareholders meeting

Gujarat Themis Biosyn (GUJTHEM) reported FY25 revenue of Rs. 150.8 Cr and PAT of Rs. 48.8 Cr. The company is now focusing solely on its core fermentation-based pharmaceutical intermediates and API business, having decided against the merger with Themis Medicare. A new API plant in Vapi commenced commercial production in May 2025, bolstering forward integration and export market presence. Key management changes include Dr. Sachin D. Patel's appointment as Managing Director. The company also completed a 1:2 bonus share issue and proposed a dividend of Re. 0.67/share. GUJTHEM shares were listed on NSE in February 2025.